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Table. Discriminatory value of aortic neck anatomic variables
Variables
Success
(No EL/MIG)
(n ¼ 140)
Failure
(EL/MIG)
(n ¼ 82)
Optimal
threshold P value
EVAR + EndoAnchors, No. 140 3
EVAR alone, No 0a 79
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Cilostazol and Freedom From Amputation After Lower Extremity
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Objectives: Cilostazol, an antiplatelet agent with vasodilating
properties, has not been well evaluated in conjunction lower extremity
revascularization (LER). We evaluated the association between cilosta-
zol and limb salvage after endovascular (ENDO) or open surgery
(OPEN) for lower extremity revascularization (LER).
Methods: Patients aged $65 years undergoing LER were iden-
tiﬁed from 2007 to 2008 MedPAR ﬁles using International Classi-
ﬁcation of Diseases, 9th Revision codes. Demographics,
comorbidities, and disease severity were obtained. Postprocedural
use of cilostazol was identiﬁed using National Drug Codes and Part
D ﬁles. Outcomes were compared using c2 analysis, Kaplan-Meier,
and Cox regression.
Results: We identiﬁed 22,954 patients undergoing LER: 8128
patients (35.4%) with claudication, 3056 (13.3%) with rest pain,
and 11,770 (51.28%) with ulceration/gangrene, and 2972 (13.0%)
patients were identiﬁed using cilostazol after LER. More patients
received ENDO (14,353) than OPEN (8601) procedures. Cilostazol
users had fewer amputations compared with nonusers at 30 days
(7.8% vs 13.4%), 90 days (10.6% vs 18.0%), and 1 year (14.8% vs
24.0%; P < .0001 for all; Fig). Compared with nonusers, patients tak-
ing cilostazol had signiﬁcantly fewer 1-year crude amputation rates:
15.0% vs 23.1% (P < .0001) for ENDO and 14.5% vs 21.7% (P <
.0001), for OPEN. In Cox proportional hazards regression with
adjustment for age, gender, race, comorbidities, type of procedure,
and atherosclerosis severity, noncilostazol users were more likely to
undergo amputation during 1 year after surgery (hazard ratio [HR],
1.15; 95% conﬁdence interval [CI], 1.02-1.23; P ¼ .02). Subset anal-
ysis revealed, noncilostazol users with renal failure (HR, 1.61; 95%
CI, 1.28-2.02; P < .0001) or diabetes (HR, 1.61; 95% CI, 1.36-
1.92; P < .0001) were more likely to undergo amputation during 1
year after surgery.
Conclusions: In patients undergoing LER, cilostazol use
was associated with improved 1-year freedom from amputation. Patients
with renal failure and diabetes demonstrated an even greater beneﬁt of cil-
ostazol use on freedom from amputation. Further studies are needed to
evaluate the beneﬁts of cilostazol after intervention.Fig. 1-year Freedom of amputation after lower extremity revascularization
with and without Cilostazol.
Neck length, mm 23 6 17 18 6 14 >18 .037
Neck diameter, mm 26 6 3 28 6 5 <26 .009
Infrarenal angulation, 36 6 18 35 6 16 <33 .774
Conicity, % increase/mm 1.1 6 0.9 1.4 6 1.1 >1.0 .545
Thrombus, mm 0.9 6 1.4 0.4 6 0.8 >1 .693
Calcium, mm 1.0 6 1.2 1.3 6 1.3 <1 .615
EL, Endoleak; EVAR, endovascular aneurysm repair; MIG, migration.
aSelected for EL or MIG after EVAR.Author Disclosures: J. D. Neel: None; R. L. Kruse: None; V. Y.
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Objectives: There is ample evidence linking aortic neck anatomy
to poor outcome after endovascular aortic aneurysm repair (EVAR),
yet the deﬁnition of hostile anatomy varies from study to study.
This current analysis was undertaken to determine which anatomic
criteria are most predictive of failure of proximal neck sealing and ﬁx-
ation after EVAR.
Methods: The study group comprised patients in the ANCHOR
clinical trial. Core laboratory analysis of three-dimensional centerline-
reformatted computed tomography (CT) scans were assessed for aortic
neck length, neck diameter, infrarenal angulation, conical conﬁguration
(percentage increase in neck diameter per mm neck length), and mural
thrombus/calcium thickness. Success or failure at the aortic neck was
deﬁned by type Ia endoleak (EL) or migration (MIG). Receiver operating
characteristic curve analysis was used to determine the optimal threshold
for discriminating success from failure. The areas under the curve were
analyzed for each anatomic variable, and signiﬁcance was assumed when
P was <.05.
Results: A total of 222 patients were included in the study: 79
(35.6%) for EndoAnchor treatment of EL/MIG in previously placed
endografts and 143 (64.4%) for EndoAnchor prophylaxis against EL/
MIG in patients with investigator-determined challenging neck anatomy.
Within the latter group, three of 143 (1.7%) subsequently failed at the
proximal neck. Over an average imaging follow-up of 9 months (range,
0-180 months), 140 of 222 patients (63.1%) were free from EL or
MIG after EVAR (success), whereas 82 (36.9%) were not (failures).
Aortic neck anatomic variables associated with success or failure are listed
in the Table.
Conclusions: Infrarenal neck diameter and length appear to be
the best differentiators of success from failure at the aortic neck.
The optimal thresholds identiﬁed by receiver operating characteristic
curve analysis should be considered when deﬁning the hostile aortic
neck.Author Disclosures: W. Jordan: Honoraria, institution receives research
funding from Aptus. K. Ouriel: Other ﬁnancial beneﬁt, is employed by
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Morbidity and Mortality After Use of an Iliac Conduit for
Endovascular Aortic Aneurysm Repair
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Objectives: Although it is generally felt that placement of an iliac
conduit for endovascular aortic aneurysm repair (EVAR) results in higher
morbidity and mortality, published literature is scarce. Our objective was
to assess 30-day outcomes after elective EVAR with an iliac conduit using
a multi-institutional database.
Fig 1. Post-EVAR survival.
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abdominal aortic aneurysm (AAA) were identiﬁed from the American Col-
lege of Surgeons National Surgical Quality Improvement Program 2005-
2011 database. Univariable and multivariable logistic regression analyses
were performed.
Results: An iliac conduit was used in 231 patients (1.6%), while the
remainder had a femoral exposure/percutaneous EVAR. Females
comprised 32% of patients with iliac conduits in contrast to 17% of those
without (P < .0001). Patients with iliac conduits were older and had a lower
body mass index (P < .05). On univariable analysis, patients with iliac con-
duits had a higher incidence of postoperative pneumonia (3.0% vs 1.1%; P ¼
.01), ventilator dependence (4.8% vs 1.0%; P < .0001), renal failure (3.0% vs
0.7%; P < .0001), myocardial infarction (3.9% vs 0.8%; P < .0001), urinary
tract infections (3.5% vs 1.6%; P ¼ .03), peripheral nerve deﬁciency (1.3% vs
0.1%; P ¼ .004), transfusion of >4 units of red blood cells during hospital
stay (17.3% vs 4.8%; P < .0001), return to operating room (9.1% vs 3.7%; P
< .0001), and death (3.0% vs 0.9%; P ¼ .001). On multivariable logistic
regression, after controlling for comorbidities and demographics, use of
an iliac conduit was not signiﬁcantly associated (P > .05) with 30-day mor-
tality or any postoperative complication other than myocardial infarction
(odds ratio, 2.6; 95% conﬁdence interval, 1.2-5.6) and peripheral nerve deﬁ-
ciency (odds ratio, 5.1; 95% conﬁdence interval, 1.2-22.2).
Conclusions: Patients with iliac conduits for EVAR have higher post-
operative morbidity and mortality. For patients with complex iliac disease,
this is a viable alternative to allow EVAR to be performed.
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Objectives: Although the EVAR-2 trial demonstrated no beneﬁt of
endovascular abdominal aortic aneurysm (AAA) repair (EVAR) in high-
risk (HR) patients, EVAR is still performed widely in this patient cohort.
This study compared the midterm outcomes after EVAR in the HR patients
with normal-risk (NR) patients. In turn, these data were compared with the
EVAR-2 data.
Methods: A retrospective review from January 2006 to December
2013 identiﬁed 247 patients (75 HR [30.4%], 172 NR [69.6%]) who un-
derwent elective EVAR for infrarenal AAA in an academic institution and
its afﬁliated Veterans Administration hospital. The same HR criteria used
in the EVAR-2 trial were used. Overall survival, graft-related complications,
and reinterventions were estimated by the Kaplan-Meier method. HR pa-
tient’s outcomes were compared with the EVAR-2 data.Fig 2. Post-EVAR intervention-free survival.Table. Baseline characteristics
Variable
Groups
P value
(NR vs HR) EVAR-2NR HR
Age, mean (SD) years 72.4 (8.4) 71.4 (8.1) .4 76.4 (6.7)
Male sex, % 91 93 .6 85
Baseline creatinine,
mean (SD)
1.1 (0.3) 1.8 (2.3) .01 1.9 (0.3)
Cardiac disease, % 47 79 <.01 67
COPD, % 21 35 .02 N/A
Current cancer Rx, % 0 29 <.01 N/A
Statin, % 72 83 .2 39
Aspirin, % 66 63 .6 58
b-Blocker, % 60 71 .2 N/A
COPD, Chronic obstructive pulmonary disease; HR, high risk; NR, normal
risk; SD, standard deviation.Results: Baseline characteristics are detailed in the Table. Use of
aspirin (63% HR vs 66% NR; P ¼ .6), statin (83% HR vs 72% NR; P
¼ .2), and b-blockers (71% HR vs 60% NR; P ¼ .2) was similar; in the
EVAR-2 trial, the corresponding use of these medications was 58%,
39%, and not available, respectively (Table). Perioperative mortality
(0% HR vs 1.2% LR; P ¼ 1.0) and early complication rates (4% HR
vs 6% LR; P ¼ .8) were similar. In contrast, perioperative mortalityin the EVAR-2 trial was 9%. At a mean follow-up of 3 years, the inci-
dence of reintervention for AAA- or graft-related complications was
7% for HR and 10% for NR patients (P ¼ .5). The 1-, 2- and 4-
year survival in HR (85%, 77%, 65%) was lower than in NR (97%,
97%, 93%; P < .001; Fig 1), but this was more favorable compared
with a 4-year survival of 36% in the EVAR-2 trial. No difference
was seen in long-term reintervention-free survival in HR and NR (P
¼ .8; Fig 2). No late AAA ruptures occurred.
Conclusions: EVAR in HR patients can be performed with excel-
lent early survival and midterm durability results. Although HR pa-
tients have inferior overall survival compared with NR patients, our
data indicate more favorable outcomes compared with the EVAR-2
trial in terms of early mortality and longer-term survival. This may
be, in part, attributable to increased statin use. Therefore, EVAR
may be a feasible treatment option for AAA in HR patients, especially
when coupled with statin use.
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